PO.IM01.01 · 免疫学
CD4⁺ T细胞中的PI3Kdelta通过IFNgamma诱导的肿瘤衰老抵御肺转移
PI3Kdelta in CD4⁺ T cells protects against lung metastases through IFNgamma-induced tumor senescence
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
PI3Kdelta是操控抗肿瘤免疫的关键淋巴细胞信号枢纽。在癌症中,大多数工作集中于抑制PI3Kdelta,尤其是在调节性T细胞中,以解除免疫抑制并增强效应T细胞对已建立肿瘤的控制。然而,肺转移仍是癌症死亡的主要原因,而PI3Kdelta调控对转移性生长的影响仍未完全阐明。受导致PI3Kdelta激活综合征(APDS)的功能获得性PIK3CD突变启发,我们探讨增强PI3Kdelta信号能否被用于预防黑色素瘤肺转移。在此,我们证明PI3Kdelta的过度激活以CD4 + T细胞依赖的方式赋予对肺部黑色素瘤转移的强效保护,该方式驱动IFNgamma介导的肿瘤细胞衰老。
我们采用具有种系或条件性过度活跃PI3Kdelta的小鼠,通过静脉注射B16F10黑色素瘤以建立肺转移。细胞特异性Cre系统确定了介导转移排斥的关键免疫群体。单细胞RNA-seq和光谱细胞术定义了免疫重塑,而清除和中和抗体以及CRISPR编辑的黑色素瘤细胞系揭示了潜在机制。
种系过度活跃PI3Kdelta小鼠发生的肺转移明显少于野生型对照,且在造血区室中诱导性激活过度活跃PI3Kdelta足以赋予保护。保护依赖于CD4 + T细胞——CD4 + T细胞特异性PI3Kdelta过度激活重现了种系保护,而B细胞、NK细胞和CD8 + T细胞特异性PI3Kdelta过度激活则未能实现。抗体清除证实CD4 +清除消除了保护,而CD8 +清除无影响。过度活跃PI3Kdelta的CD4 + T细胞表现出增强的Th1分化,IFNgamma增加,而IFNgamma中和消除了对转移的保护。机制上,肿瘤控制需要癌细胞中的IFNGR1/JAK1信号而非TNFR1,且独立于肿瘤MHC-I或MHC-II表达而发挥作用。保护机制汇聚于IFNgamma诱导的肿瘤衰老,因为来自过度活跃PI3Kdelta小鼠的肺转移灶显示SA-beta-gal活性增加,表明CD4 + T细胞通过强制肿瘤细胞衰老来阻止转移进展。
我们的发现揭示了一条新型保护轴,其中CD4 + T细胞中过度活跃的PI3Kdelta信号驱动一种1型偏向的肺部抗转移微环境。这将CD4 + T细胞从"辅助者"提升为抗转移效应细胞,利用IFNgamma依赖的肿瘤内在衰老实现持久的免疫控制。这些结果揭示过度活跃PI3Kdelta是一把双刃剑:虽然在APDS中具有致病性,但它增强了对转移的免疫监视,为通过增强PI3Kdelta信号预防转移进展提供了新的治疗途径。
查看英文原文 English abstract
PI3Kdelta is a key lymphocyte signaling hub for manipulating antitumor immunity. In cancer, most work has centered on inhibiting PI3Kdelta, particularly in regulatory T cells, to relieve immunosuppression and enhance effector T cell control of established tumors. Yet lung metastasis remains a leading cause of cancer mortality, and the impact of PI3Kdelta modulation on metastatic outgrowth remains incompletely understood. Inspired by gain-of-function PIK3CD mutations that cause activated PI3Kdelta syndrome (APDS), we ask whether enhancing PI3Kdelta signaling can be harnessed to prevent melanoma lung metastases. Here, we demonstrate that hyperactivation of PI3Kdelta confers robust protection against pulmonary melanoma metastases in a CD4 + T cell - dependent manner that drives IFNgamma-mediated tumor cell senescence.
We employed mice with germline or conditional hyperactive PI3Kdelta, challenged intravenously with B16F10 melanoma to establish lung metastasis. Cell-specific Cre systems identified critical immune populations mediating metastasis rejection. Single-cell RNA-seq and spectral cytometry defined immune remodeling, while depleting and neutralizing antibodies as well as CRISPR-edited melanoma lines revealed underlying mechanism.
Germline hyperactive-PI3Kdelta mice developed markedly fewer lung metastases than wild-type controls, and inducible activation of hyperactive PI3Kdelta in the hematopoietic compartment was sufficient to confer protection. Protection was dependent on CD4 + T cells - CD4 + T cell specific PI3Kdelta hyperactivation recapitulated germline protection, while B cell, NK cell and CD8 + T cell specific PI3Kdelta hyperactivation did not. Antibody depletions confirmed that CD4 + depletion abolished protection while CD8 + depletion had no effect. Hyperactive PI3Kdelta CD4 + T cells showed enhanced Th1 differentiation with increased IFNgamma and IFNgamma-neutralization eliminated the protection against metastasis. Mechanistically, tumor control required IFNGR1/JAK1 signaling in cancer cells but not TNFR1, and operated independent of tumor MHC-I or MHC-II expression. The protective mechanism converged on IFNgamma-induced tumor senescence, as lung metastases from hyperactive-PI3Kdelta mice displayed increased SA-beta-gal activity, indicating that CD4 + T cells halt metastatic progression by enforcing tumor cell senescence.
Our findings reveal a novel protective axis where hyperactive PI3Kdelta signaling in CD4 + T cells drives a type 1-skewed pulmonary anti-metastasis microenvironment. This elevates CD4 + T cells from "helpers" to anti-metastatic effectors using IFNgamma-dependent tumor-intrinsic senescence to achieve durable immune control. These results reveal hyperactive PI3Kdelta as a double-edged sword: while pathogenic in APDS, it reinforces immune surveillance of metastasis, offering new therapeutic avenues for preventing metastatic progression by enhancing PI3Kdelta signaling.
利益披露 Disclosure
L. Tang, None..
G. Cooper, None..
L. Porter, None..
S. joon Kim, None..
E. Armingol, None..
O. Burton, None..
J. E. Thaventhiran, None..
W. T. Khaled, None..
R. Vento-tormo, None..
R. Roychoudhuri, None..
K. Okkenhaug, None.